The Effect of Biofeedback on Constipation, Sleep, Depression, Anxiety and Quality of Life in Patients with Dyssynergic Defecation: a QUASI Experimental Study (Before and After Study).
{"title":"The Effect of Biofeedback on Constipation, Sleep, Depression, Anxiety and Quality of Life in Patients with Dyssynergic Defecation: a QUASI Experimental Study (Before and After Study).","authors":"Seyede Zahra Emami Razavi, Alaleh Amirak, Negin Rahimi, Maryam Hosseini, Mohaddeseh Azadvari, Maryam Rafiei","doi":"10.1007/s10484-024-09680-z","DOIUrl":null,"url":null,"abstract":"<p><p>Dyssynergic defecation(DD) is the inability to coordinate abdominal and anorectal muscle contraction during defecation. Patients with constipation often report poor quality of life, sleep issues, and increased risk of mood disorders. Biofeedback is a recommended treatment for DD. we evaluated the effect of EMG-biofeedback on constipation symptoms as the primary outcome and also on insomnia, mood disorders (depression and anxiety), and quality of life as secondary outcomes in patients with dyssynergic defecation. Thirty-one patients with DD (74.2% women, mean age 46.23 ± 13.42 years), diagnosed using Rome IV criteria, Bristol Stool Form Scale, and anorectal manometry, were included. Patients underwent six to ten sessions of EMG-based biofeedback. We evaluated symptoms using the Wexner constipation questionnaire, Visual Analog Scale (VAS), SF-36 for quality of life, Insomnia Severity Index (ISI), and Hamilton questionnaires for anxiety and depression (HAM-A and HAM-D) before and after treatment. As consistent with study hypotheses, the Wexner scores significantly improved after biofeedback (p < 0.0001, t = 6.98). ISI scores improved (p = 0.01, t = 2.74), as did VAS scores (p < 0.0001, t = 5.14). HAM-A and HAM-D scores showed significant reductions (HAM-A: p = 0.0001, t = 5.01; HAM-D: p = 0.003, t = 2.17). However, SF-36 did not show significant improvement in quality of life (p > 0.05, t = -0.93). Biofeedback effectively improved constipation symptoms, insomnia, and mood disorders but did not impact quality of life.</p>","PeriodicalId":47506,"journal":{"name":"Applied Psychophysiology and Biofeedback","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Psychophysiology and Biofeedback","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1007/s10484-024-09680-z","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Dyssynergic defecation(DD) is the inability to coordinate abdominal and anorectal muscle contraction during defecation. Patients with constipation often report poor quality of life, sleep issues, and increased risk of mood disorders. Biofeedback is a recommended treatment for DD. we evaluated the effect of EMG-biofeedback on constipation symptoms as the primary outcome and also on insomnia, mood disorders (depression and anxiety), and quality of life as secondary outcomes in patients with dyssynergic defecation. Thirty-one patients with DD (74.2% women, mean age 46.23 ± 13.42 years), diagnosed using Rome IV criteria, Bristol Stool Form Scale, and anorectal manometry, were included. Patients underwent six to ten sessions of EMG-based biofeedback. We evaluated symptoms using the Wexner constipation questionnaire, Visual Analog Scale (VAS), SF-36 for quality of life, Insomnia Severity Index (ISI), and Hamilton questionnaires for anxiety and depression (HAM-A and HAM-D) before and after treatment. As consistent with study hypotheses, the Wexner scores significantly improved after biofeedback (p < 0.0001, t = 6.98). ISI scores improved (p = 0.01, t = 2.74), as did VAS scores (p < 0.0001, t = 5.14). HAM-A and HAM-D scores showed significant reductions (HAM-A: p = 0.0001, t = 5.01; HAM-D: p = 0.003, t = 2.17). However, SF-36 did not show significant improvement in quality of life (p > 0.05, t = -0.93). Biofeedback effectively improved constipation symptoms, insomnia, and mood disorders but did not impact quality of life.
期刊介绍:
Applied Psychophysiology and Biofeedback is an international, interdisciplinary journal devoted to study of the interrelationship of physiological systems, cognition, social and environmental parameters, and health. Priority is given to original research, basic and applied, which contributes to the theory, practice, and evaluation of applied psychophysiology and biofeedback. Submissions are also welcomed for consideration in several additional sections that appear in the journal. They consist of conceptual and theoretical articles; evaluative reviews; the Clinical Forum, which includes separate categories for innovative case studies, clinical replication series, extended treatment protocols, and clinical notes and observations; the Discussion Forum, which includes a series of papers centered around a topic of importance to the field; Innovations in Instrumentation; Letters to the Editor, commenting on issues raised in articles previously published in the journal; and select book reviews. Applied Psychophysiology and Biofeedback is the official publication of the Association for Applied Psychophysiology and Biofeedback.